Australia Non Invasive Prenatal Testing Market Size & Outlook
- Clinical Diagnostics
- Genetic Testing
- Non Invasive Prenatal Testing Market Outlook
- Genetic Testing
Global Market
Related Markets
Ask a question about the non invasive prenatal testing market
Australia non invasive prenatal testing market highlights
- The Australia non invasive prenatal testing market generated a revenue of USD 77.9 million in 2023 and is expected to reach USD 152.3 million by 2030.
- The Australia market is expected to grow at a CAGR of 10.2% from 2024 to 2030.
- In terms of segment, 13-24 weeks was the largest revenue generating gestation period in 2023.
- 0-12 weeks is the most lucrative gestation period segment registering the fastest growth during the forecast period.
Non invasive prenatal testing market data book summary
| Market revenue in 2023 | USD 77.9 million |
| Market revenue in 2030 | USD 152.3 million |
| Growth rate | 10.2% (CAGR from 2024 to 2030) |
| Largest segment | 13-24 weeks |
| Fastest growing segment | 0-12 weeks |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
| Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
Other key industry trends
- In terms of revenue, Australia accounted for 1.8% of the global non invasive prenatal testing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China non invasive prenatal testing market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 247.6 million by 2030.
In Australia, TGA regulates the pricing and reimbursement of IVD products under the Therapeutics Goods Act 1989 and its delegated legislation. The TGA is responsible for assessing, evaluating, and monitoring medicines manufactured and supplied in Australia.
The Australian government launched the Pharmaceutical Benefits Scheme under the National Health Act 1953 to provide different products at subsidized and free of cost to patients. Australia has a codependent submission process to evaluate the medicine and the companion diagnostic products.
For instance, the Medical Services Advisory Committee and Pharmaceutical Benefits Advisory Committee assess individual and combined evidence. Both committees must provide a favorable recommendation for the test to be included on the Medicare Benefits Schedule (MBS) and the medication on the Pharmaceutical Benefits Scheme.
No credit card required*
Publish Date: Dec 15, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Non Invasive Prenatal Testing Market Scope
Non Invasive Prenatal Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Quest Diagnostics Inc | View profile | 48,000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | www.questdiagnostics.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Eurofins Scientific SE | View profile | 61,798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | www.eurofins.com |
| Myriad Genetics Inc | View profile | 2,700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | www.myriad.com |
| Natera Inc | View profile | 3,293 | 13011 McCallen Pass, Building A Suite 100, Austin, TX, United States, 78753 | www.natera.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| Centogene NV Ordinary Shares | View profile | 493 | Am Strande 7, Rostock, MV, Germany, 18055 | www.centogene.com |
| Biora Therapeutics | View profile | 51-100 | Carlsbad, California, United States, North America | www.bioratherapeutics.com/ |
Australia Non Invasive Prenatal Testing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Non Invasive Prenatal Testing Market Outlook will help companies and investors design strategic landscapes.
13-24 Weeks was the largest segment with a revenue share of 57.25% in 2023.
Horizon Databook has segmented the Australia non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
In Australia, TGA regulates the pricing and reimbursement of IVD products under the Therapeutics Goods Act 1989 and its delegated legislation. The TGA is responsible for assessing, evaluating, and monitoring medicines manufactured and supplied in Australia.
The Australian government launched the Pharmaceutical Benefits Scheme under the National Health Act 1953 to provide different products at subsidized and free of cost to patients. Australia has a codependent submission process to evaluate the medicine and the companion diagnostic products.
For instance, the Medical Services Advisory Committee and Pharmaceutical Benefits Advisory Committee assess individual and combined evidence. Both committees must provide a favorable recommendation for the test to be included on the Medicare Benefits Schedule (MBS) and the medication on the Pharmaceutical Benefits Scheme.
- Australia Non Invasive Prenatal Testing Market Gestation Period Outlook (Revenue, USD Million , 2018-2030)
- 0-12 weeks
- 13-24 weeks
- 25-36 weeks
- Australia Non Invasive Prenatal Testing Market Risk Outlook (Revenue, USD Million , 2018-2030)
- High & Average Risk
- Low Risk
- Australia Non Invasive Prenatal Testing Market Method Outlook (Revenue, USD Million , 2018-2030)
- Ultrasound Detection
- Biochemical Screening Tests
- Cell-Free DNA in Maternal Plasma Tests
- Australia Non Invasive Prenatal Testing Market Technology Outlook (Revenue, USD Million , 2018-2030)
- NGS
- Array Technology
- PCR
- Others
- Australia Non Invasive Prenatal Testing Market Product Outlook (Revenue, USD Million , 2018-2030)
- Consumables & Reagents
- Instruments
- Australia Non Invasive Prenatal Testing Market Application Outlook (Revenue, USD Million , 2018-2030)
- Trisomy
- Microdeletion Syndrome
- Other Applications
- Australia Non Invasive Prenatal Testing Market End-use Outlook (Revenue, USD Million , 2018-2030)
- Hospitals & Clinics
- Diagnostic Laboratories
Reasons to subscribe to Non Invasive Prenatal Testing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Non Invasive Prenatal Testing Market Outlook databook
- Our clientele includes a mix of Non Invasive Prenatal Testing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia Non Invasive Prenatal Testing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia Non Invasive Prenatal Testing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Australia Non Invasive Prenatal Testing Market, 2018-2030 (US$M)
Australia non invasive prenatal testing market statistics, by gestation period, 2018-2030 (US$M)
